



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/888,840	06/25/2001	Gary T. Wang	13780-2	9459

4743 7590 09/13/2002

MARSHALL, GERSTEIN & BORUN
6300 SEARS TOWER
233 SOUTH WACKER
CHICAGO, IL 60606-6357

EXAMINER

HABTE, KAHSAY

ART UNIT	PAPER NUMBER
1624	10

DATE MAILED: 09/13/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/888,840	WANG ET AL.
	Examiner Kahsay Habte, Ph. D.	Art Unit 1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 21 August 2002.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-27 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) 1-27 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____.
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____.	6) <input type="checkbox"/> Other: _____.

DETAILED ACTION

1. Claims 1-27 are pending.

Response to Amendment

2. Applicant's amendment filed 8/21/02 in response to the previous Office Action (Paper No. 7) is acknowledged. Upon further review of the amendment in which applicants added new claims 10-27, it is deemed necessary to restrict the inventions again. This new restriction requirement will substitute the earlier one.

Restriction/Election

3. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-14 (in part) and 16-27 (in part), drawn to compounds, compositions, and method of use, where R¹ or R³ in the structure is pyrimidinyl, classified in class 544, subclass various.
 - II. Claims 1-14 (in part) and 16-27 (in part), drawn to compounds, compositions, and method of use, where R¹ or R³ in the structure is pyridinyl, classified in class 546, subclass various.
 - III. Claims 1-15 (in part) and 17-27 (in part), drawn to compounds, compositions, and method of use, where R¹ or R³ in the structure is thiazolyl, classified in class 548, subclass various.

IV. Claims 1-15 (in part) and 17-27 (in part), drawn to compounds compositions, and method of use, where R¹ or R³ in the structure is oxazolyl, classified in class 548, subclass various.

V. Claims 1-27 (in part), drawn to others, classified in various classes such as 540, 544, 546, 548, 564; and subclass various.

The inventions are distinct, each from the other because of the following reasons: Groups I-V are directed to structurally dissimilar compounds such that the variable core created by the varying definitions of R¹ or R³ in the structure do not belong to the same recognized class of chemical compounds in the art, and references anticipating one invention, would not render obvious the others. For example, Group I that is drawn to pyrimidinyl substituent in R¹ or R³ is different from Groups II-V, because pyrimidinyl ring (a six-membered ring with 2 nitrogens) is not present in Groups II-V. Group II is different from Groups I and III-V, because pyridinyl substituent (one nitrogen in a six-membered ring) is not present in Groups I, and III-V. Group III is drawn to thiazolyl substituent (five-membered ring with N and S) and is different from Groups I-II, and IV-V. Group IV is drawn to oxazolyl (five-membered ring with N and O) and is different from Groups I-III and V. Group V is different from Groups I-IV, because it is drawn to R¹ or R³ substituents that are not covered by Groups I-IV (e.g. R¹ or R³ = phenyl, cyclohexyl, cyclopentyl, or other heterocyclic rings). Thus, separate searches in the literature as well as in the U.S. Patent Classification System would be required. Each group's compounds are made and used independently of each other and could support

separate patents. The compounds differ significantly in chemical structures. One skilled in the art would not consider such diverse structure equivalents of each other.

If Group I-V is elected; tentative election of a single species is required.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions anticipated by prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Because these inventions are distinct for the reasons given above and have acquired separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

A telephone call was made to Mr. Kristin Hubner on June 12, 2002 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

It is also recommended that applicants delete non-elected subject matter in responding to this Office Action. For example, new added claim 14 contains 4 chemical structures that belong to different inventions.

Conclusion

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kahsay Habte, Ph. D. whose telephone number is (703) 308-4717. The examiner can normally be reached on M-F (9.00AM- 5:30PM).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on 703-308-4716. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.


Kahsay Habte, Ph. D.

Examiner
Art Unit 1624

KH
September 12, 2002


Mukund J. Shah
Supervisory Patent Examiner
Art Unit 1624